-
Mashup Score: 5
The phase III RESILIENT Part 2 trial has shown no overall survival benefit with second-line liposomal irinotecan vs topotecan in patients with small cell lung cancer whose disease progressed on or aft…
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Alectinib Approved as Adjuvant Treatment for ALK-Positive Non–Small Cell Lung Cancer - 26 day(s) ago
On April 18, the U.S. Food and Drug Administration (FDA) approved the tyrosine kinase inhibitor alectinib (Alecensa) for adjuvant treatment after tumor resection in patients with ALK-positive non–smal…
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
The phase III ALINA trial has shown significantly improved disease-free survival with adjuvant alectinib vs platinum-based chemotherapy in patients with resected ALK-positive NSCLC.
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
On November 15, 2023, repotrectinib (Augtyro) was approved for locally advanced or metastatic ROS1 fusion–positive non–small cell lung cancer (NSCLC). 1 This is the first U.S. Food and Drug Administration approval that includes patients with ROS1 -positive NSCLC who have previously received a ROS1 tyrosine kinase inhibitor and those who are tyrosine kinase inhibitor–naive. Approval was based on the multicenter mu lticohort TRIDENT-1 trial (ClinicalTrials.gov identifier NCT03093116), including 71 ROS1
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Osimertinib With Chemotherapy for EGFR-Mutated NSCLC - The ASCO Post - 2 month(s) ago
On February 16, 2024, osimertinib (Tagrisso) was approved by the U.S. Food and Drug Administraton (FDA) with pemetrexed and platinum-based chemotherapy for patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) with tumors having EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test, and no prior systemic therapy for advanced disease. 1 Approval was based on the open- label phase III FLAURA2 trial (ClinicalTrials.gov identifier NCT04035486). In
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
On February 16, the U.S. Food and Drug Administration (FDA) approved osimertinib (Tagrisso) with platinum-based chemotherapy for patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. Efficacy was evaluated in FLAURA2 (ClinicalTrials.gov identifier NCT04035486), an open-label, randomized trial of 557 patients with EGFR exon 19 deletion or exon 21 L858R mutation–positive
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1FDA Approves Tepotinib for Metastatic NSCLC - The ASCO Post - 3 month(s) ago
On February 15, the U.S. Food and Drug Administration (FDA) granted traditional approval to the kinase inhibitor tepotinib (Tepmetko) for adult patients with metastatic non–small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14–skipping alterations. The agent is directed against MET. Tepotinib was previously granted accelerated approval for this indication on February 3, 2021, based on initial overall response rate and duration of response in the VISION trial (ClinicalTria
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Osimertinib vs Sequential Gefitinib/Osimertinib in Advanced EGFR-Mutant NSCLC - The ASCO Post - 3 month(s) ago
As reported in the Journal of Clinical Oncology by Jordi Remon, MD, PhD, and colleagues, the final analysis of overall survival in the phase II EORTC APPLE trial showed no significant difference between the strategies of upfront osimertinib vs sequential gefitinib/osimertinib in previously untreated patients with advanced EGF R -mutant non–small cell lung cancer (NSCLC). In the multicenter trial, 156 patients were allocated between November 2017 and February 2020 to one of two treatment strategies:
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Rate of Second Primary Lung Cancers With Lobar vs Sublobar Resection of T1aN0 NSCLC - The ASCO Post - 4 month(s) ago
As reported in the Journal of Clinical Oncology by Thomas E. Stinchcombe, MD, and colleagues, an analysis from the phase III Cancer and Leukemia Group B 140503/Alliance trial has shown high rates of second primary lung cancers with both sublobar and lobar resections for T1aN0 non–small cell lung cancer (NSCLC). In the trial, 697 patients with stage T1aN0 NSCLC (using the TNM staging system 7th edition) were randomly assigned between June 2007 and March 2017 to undergo lobar (n = 357) vs sublobar (n =
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4EGFR-Mutated Advanced NSCLC CNS Efficacy With Combination of Osimertinib and Chemotherapy - The ASCO Post - 5 month(s) ago
In a subgroup analysis from the phase III FLAURA2 trial reported in the Journal of Clinical Oncology, Pasi A. Jänne, MD, PhD, and colleagues found the combination of osimertinib and chemotherapy improved central nervous system (CNS) efficacy vs osimertinib alone in the first-line treatment of patients with EGFR -mutated advanced non–small cell lung cancer (NSCLC). FLAURA2 also showed that osimertinib/chemotherapy produced significantly longer progression-free survival vs osimerti nib monotherapy among
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
Liposomal Irinotecan vs Topotecan in Relapsed Small Cell Lung Cancer https://t.co/QOiXgGhYP1 #LCSM #lungcancer #oncology